Valeant makes hedge fund-assisted play for Allergan

Save

An acquisition of Allergan by Valeant, which could be valued at substantially more than $40bn given Allergan's current market cap, makes a lot of sense. Both companies have heavy interests in dermatology and ophthalmology, but Valeant chairman and CEO…